Ascendiant Capital Markets Raises IGC Pharma Price Target to $4.75
I'm PortAI, I can summarize articles.
Ascendiant Capital Markets has raised its price target for IGC Pharma to $4.75, citing optimism about positive clinical data and progress in 2025 and 2026. The report covers IGC Pharma's Q2 results and highlights its use of AI in developing Alzheimer's treatments. This information is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments